Difference between revisions of "Part:BBa K5333000:Experience"
(→Applications of BBa_K5333000) |
|||
| Line 5: | Line 5: | ||
===Applications of BBa_K5333000=== | ===Applications of BBa_K5333000=== | ||
| + | |||
| + | The original sequence build for the gBlock is encoded here | ||
| + | |||
| + | pET28-His-GR | ||
| + | TCCTTTCGGGCTTTGTTACTTCTGATGAAACAGAAGTTTTTTGATATTGCCATTTGAATATTTTGGTATCTGATTGGTGATGATTTCAGCTAACATCTCGGGGAATTCAATACTCATGGTCTTATCCAAGAATGTCTGGAAGCAATAGTTAAGCAGATTTTCGACCACTTCATGCATAGAATCCAAGAGTTTTGTCAGTTGGTAAAAGCGCTGCCAGTTCTGGCTGGAGTTGCCTTCCCGTTTGACAATGGCTTTGCCCAGCTCTTTGATGTAGGTCATGCGAATTTCATCAAACAGCTCCTGGCTCTTCAGACCGTCCTTCGGGACTGAAGAGAGAAGCAGTAAGGTTTTCATACAGAGATATTCTTCATACGATACCTGAAGACGATGCAACTCCGAGGAAACATACAGCATGTGTTTACATTGGTCGTACATGCACGGCAGGGTCATGCGCTGCTCATTAATAATCAGATCAGGAGCAAAGCACAGCAGGTTTGCACTTGACTGACGATAGCTGCGCCACCCCAGCGCAAAGGCCATAAGAAACATCCAGGAGTACTGCAGCAAGGTCATTTGGTCATCCAGGTGTAAGTTGCGGAAACCCGGGATCGCTTTTGCCCATTTCACCGCTGCAATCACTTGACGCCCTCCCAGCATGTTCAGCGTAGTCATGATCCGCCAAGTAGAGTCCGGAACCGAGCTATCGTAACCGGCATATAACACTTCAGGTTCAATAACTTCCAACAGACTCACCAGCGTCGGCGTGAGTTGTGGTAACGTCGCGGGAACGCTGCCACGCGGTACCAGGCCATGATGGTGGTGATGGTGACCTTTTTTCATGGTATATCTCCTTCT | ||
| + | |||
| + | The original sequence is functional, however the modified sequence in the parts registry is the subsitute that fits the guidelines, as the original sequence includes illegal restriction enzyme cleavage sites. | ||
| + | |||
| + | Even thought the sequence used is directly derived from the literature (He et al.,2014) includes specific mutations to improve the solubility of the protein, we still encounter challenges to obtain the protein in the soluble fraction according to our laboratory results. | ||
===User Reviews=== | ===User Reviews=== | ||
Latest revision as of 21:09, 1 October 2024
This experience page is provided so that any user may enter their experience using this part.
Please enter
how you used this part and how it worked out.
Applications of BBa_K5333000
The original sequence build for the gBlock is encoded here
pET28-His-GR TCCTTTCGGGCTTTGTTACTTCTGATGAAACAGAAGTTTTTTGATATTGCCATTTGAATATTTTGGTATCTGATTGGTGATGATTTCAGCTAACATCTCGGGGAATTCAATACTCATGGTCTTATCCAAGAATGTCTGGAAGCAATAGTTAAGCAGATTTTCGACCACTTCATGCATAGAATCCAAGAGTTTTGTCAGTTGGTAAAAGCGCTGCCAGTTCTGGCTGGAGTTGCCTTCCCGTTTGACAATGGCTTTGCCCAGCTCTTTGATGTAGGTCATGCGAATTTCATCAAACAGCTCCTGGCTCTTCAGACCGTCCTTCGGGACTGAAGAGAGAAGCAGTAAGGTTTTCATACAGAGATATTCTTCATACGATACCTGAAGACGATGCAACTCCGAGGAAACATACAGCATGTGTTTACATTGGTCGTACATGCACGGCAGGGTCATGCGCTGCTCATTAATAATCAGATCAGGAGCAAAGCACAGCAGGTTTGCACTTGACTGACGATAGCTGCGCCACCCCAGCGCAAAGGCCATAAGAAACATCCAGGAGTACTGCAGCAAGGTCATTTGGTCATCCAGGTGTAAGTTGCGGAAACCCGGGATCGCTTTTGCCCATTTCACCGCTGCAATCACTTGACGCCCTCCCAGCATGTTCAGCGTAGTCATGATCCGCCAAGTAGAGTCCGGAACCGAGCTATCGTAACCGGCATATAACACTTCAGGTTCAATAACTTCCAACAGACTCACCAGCGTCGGCGTGAGTTGTGGTAACGTCGCGGGAACGCTGCCACGCGGTACCAGGCCATGATGGTGGTGATGGTGACCTTTTTTCATGGTATATCTCCTTCT
The original sequence is functional, however the modified sequence in the parts registry is the subsitute that fits the guidelines, as the original sequence includes illegal restriction enzyme cleavage sites.
Even thought the sequence used is directly derived from the literature (He et al.,2014) includes specific mutations to improve the solubility of the protein, we still encounter challenges to obtain the protein in the soluble fraction according to our laboratory results.
User Reviews
UNIQdb9345e94217bafb-partinfo-00000000-QINU UNIQdb9345e94217bafb-partinfo-00000001-QINU